Background: Receptor Tyrosine Kinases (RTKs) play critical roles in a variety of cellular
processes including growth, differentiation and angiogenesis, and in the development and progression
of many types of cancer. Mesenchymal-Epithelial Transition Factor (c-Met) kinase is one
of the types of RTKs and has become an attractive target for anti-tumor drug designing. c-Met inhibitors
have a broad prospect in tumor prevention, chemotherapy, biotherapy, and especially in tumor
Objective: The purpose of this article is to review recent research progress of c-Met inhibitors reported
in patents since 2015.
Methods: A comprehensive Scifinder and Web of Science literature review was conducted to identify
all c-Met inhibitors published in patents since 2015.
Results: There are two kinds of c-Met inhibitors, one is from natural products, and the other one is
of synthetic origin. Most of these c-Met inhibitors show potent in vivo and in vitro antitumor activities
and have potential in the treatment of cancers.
Conclusion: c-Met kinase inhibitors have emerged as an exciting new drug class for the treatment
of all kinds of cancers, especially the Non-Small Cell Lung Cancer (NSCLC) with tumor resistance.
More studies should be conducted on natural products to find novel c-Met kinase inhibitors.